Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled liposomal + free ciprofloxacin for non-cystic fibrosis bronchiectasis with chronic Pseudomonas infection
ACTRN12609000578202Phase 2Recruiting
- Sponsor
- Paradigm Biopharmaceuticals
- Start
- Oct 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of inhaled liposomal ciprofloxacin and ciprofloxacin in bronchiectasis and Pseudomonal infection (2 arms), sponsored by Paradigm Biopharmaceuticals. Primary endpoint: Mean change in Pseudomonas aeruginosa sputum density. Started Oct 2009; status: recruiting.
02
Drugs
inhaled liposomal ciprofloxacinciprofloxacin
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on ACTRN12609000578202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000578202.